Vincenzo Musolino

Dr. Vincenzo Musolino

Institute of Research for Food Safety and Health (IRC-FSH), Department of Health Sciences, University “Magna Graecia” of Catanzaro, Catanzaro, Italy

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 August 2020 in Biomedicines
Verified
Journal Article
Open access
PDF file
FOFrancesca Oppedisano
Francesca Oppedisano
RMRoberta Macrì
Roberta Macrì
Micaela GliozziMicaela Gliozzi
Micaela Gliozzi
VMVincenzo Musolino
Vincenzo Musolino
CCCristina Carresi
Cristina Carresi
VMVincenzo Mollace
Vincenzo Mollace
Polyunsaturated fatty acids (n-3 PUFAs) are long-chain polyunsaturated fatty acids with 18, 20 or 22 carbon atoms, which have been found able to counteract cardiovascular diseases. Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), in particular, have been found to produce both vaso- and cardio-protective response via modulation of membrane phospholipids thereby improving cardiac mitochondrial functions and energy production. However, antioxidant properties of n-3 PUFAs, along with their anti-inflammatory effect in both blood vessels and cardiac cells, seem to exert beneficial effects in cardiovascular impairment. In fact, dietary supplementation with n-3 PUFAs has been demonstrated to reduce oxidative stress-related mitochondrial dysfunction and endothelial cell apoptosis, an effect occurring via an increased activity of endogenous antioxidant enzymes. On the other hand, n-3 PUFAs have been shown to counteract the release of pro-inflammatory cytokines in both vascular tissues and in the myocardium, thereby restoring vascular reactivity and myocardial performance. Here we summarize the molecular mechanisms underlying the anti-oxidant and anti-inflammatory effect of n-3 PUFAs in vascular and cardiac tissues and their implication in the prevention and treatment of cardiovascular disease.

Verified
Journal Article
Open access
PDF file
Jessica MaiuoloJessica Maiuolo
Jessica Maiuolo
RBRosa Maria Bulotta
Rosa Maria Bulotta
SRStefano Ruga
Stefano Ruga
SNSaverio Nucera
Saverio Nucera
RMRoberta Macrì
Roberta Macrì
VMVincenzo Mollace
Vincenzo Mollace
The gut microbiota is a diverse bacterial community consisting of approximately 2000 species, predominantly from five phyla: Firmicutes, Bacteroidetes, Actinobacteria, Proteobacteria, and Verrucomicrobia. The microbiota’s bacterial species create distinct compounds that impact the host’s health, including well-known short-chain fatty acids. These are produced through the breakdown of dietary fibers and fermentation of undigested carbohydrates by the intestinal microbiota. The main short-chain fatty acids consist of acetate, propionate, and butyrate. The concentration of butyrate in mammalian intestines varies depending on the diet. Its main functions are use as an energy source, cell differentiation, reduction in the inflammatory process in the intestine, and defense against oxidative stress. It also plays an epigenetic role in histone deacetylases, thus helping to reduce the risk of colon cancer. Finally, butyrate affects the gut–brain axis by crossing the brain–blood barrier, making it crucial to determine the right concentrations for both local and peripheral effects. In recent years, there has been a significant amount of attention given to the role of dietary polyphenols and fibers in promoting human health. Polyphenols and dietary fibers both play crucial roles in protecting human health and can produce butyrate through gut microbiota fermentation. This paper aims to summarize information on the key summits related to the negative correlation between intestinal microbiota diversity and chronic diseases to guide future research on determining the specific activity of butyrate from polyphenols and dietary fibers that can carry out these vital functions.

1 January 2021 in Pharmacological Research
Verified
Journal Article
Closed access
Micaela GliozziMicaela Gliozzi
Micaela Gliozzi
VMVincenzo Musolino
Vincenzo Musolino
FBFrancesca Bosco
Francesca Bosco
MSMiriam Scicchitano
Miriam Scicchitano
FSFederica Scarano
Federica Scarano
VMVincenzo Mollace
Vincenzo Mollace

7 April 2016 in Journal of Cachexia, Sarcopenia and Muscle
Verified
Journal Article
Open access
PDF file
VMVincenzo Musolino
Vincenzo Musolino
SPSandra Palus
Sandra Palus
ATAnika Tschirner
Anika Tschirner
CDCathleen Drescher
Cathleen Drescher
MGMicaela Gliozzi
Micaela Gliozzi
JSJochen Springer
Jochen Springer
Background: Cachexia is a complex metabolic syndrome associated with cancer. One of the features of cachexia is the loss of muscle mass, characterized by an imbalance between protein synthesis and protein degradation. Muscle atrophy is caused by the hyperactivation of some of the main cellular catabolic pathways, including autophagy. Cachexia also affects the cardiac muscle. As a consequence of the atrophy of the heart, cardiac function is impaired and mortality is increased. Anti‐cachectic therapy in patients with cancer cachexia is so far limited to nutritional support and anabolic steroids. The use of the appetite stimulant megestrol acetate (MA) has been discussed as a treatment for cachexia.Methods: In this study the effects of MA were tested in cachectic tumour‐bearing rats (Yoshida AH‐130 ascites hepatoma). Rats were treated daily with 100 mg/kg of MA or placebo starting one day after tumour inoculation, and for a period of 16 days. Body weight and body composition were assessed at baseline and at the end of the study. Cardiac function was analysed by echocardiography at baseline and at day 11. Locomotor activity and food intake were assessed before tumour inoculation and at day 11. Autophagic markers were assessed in gastrocnemius muscle and heart by western blot analysis.Results: Treatment with 100 mg/kg/day MA significantly attenuated the loss of body weight (−9 ± 12%,P < 0.05) and the wasting of lean and fat mass (−7.0 ± 6% and −22.4 ± 3 %,P < 0.001 andP < 0.05, respectively). Administration of 100 mg/kg/day MA significantly protected the heart from general atrophy (633.8 ± 30 mg vs. placebo 474 ± 13 mg,P < 0.001). Tumour‐bearing rats displayed cardiac dysfunction, as indicated by the significant impairment of the left ventricular ejection fraction, the left ventricular fractional shortening, the stroke volume, the end dyastolic volume, and the end systolic volume. In contrast, MA significantly improved left ventricular ejection fraction, left ventricular fractional shortening, and left ventricular end systolic volume. Western blotting analysis showed an upregulation of the autophagic pathway in the gastrocnemius and hearts of the placebo‐treated tumour‐bearing rats. Treatment with MA, however, was able to modulate the autophagic markers (e.g. Beclin‐1, p62, TRAF6, and LC3) in the gastrocnemius and in the hearts of tumour‐bearing rats. Most importantly, 100 mg/kg/day MA reduced mortality [hazard ratio (HR): 0.44; 95%CI: 0.20–1.00;P = 0.0486].Conclusions: Megestrol acetate improved survival and reduced wasting through a marked downregulation of autophagy, occurring in both skeletal and heart muscle, the latter effect leading to a significant improvement of cardiac function. Our data suggest that MA might represent a valuable strategy to counteract the development of cancer cachexia‐induced cardiomyopathy.

21 February 2022 in Veterinary Sciences
Verified
Journal Article
Open access
PDF file
Roberto BavaRoberto Bava
Roberto Bava
Fabio CastagnaFabio Castagna
Fabio Castagna
CPCristian Piras
Cristian Piras
VMVincenzo Musolino
Vincenzo Musolino
Carmine LupiaCarmine Lupia
Carmine Lupia
Vincenzo MusellaVincenzo Musella
Vincenzo Musella
The emergence of resistance to chemical drugs in beekeeping is becoming a phenomenon of widespread concern. One promising alternative to the use of chemicals is entomopathogenic organisms that are environmentally friendly and are capable of stopping the expression of resistance once it has evolved. In the recent past, the scientific community has carried out several experiments addressing the use of microbiological control agents. In particular, experimental studies using entomopathogenic fungi have had more success in honey bee research. With their adherence properties and their ability to digest the cuticle and overcome the host defense mechanism, they could be a suitable ingredient in bioacaricides. Several promising fungi have been identified in the search for effective means to control pest populations. The data obtained from the different experiments are interesting and often favorable to their use, but there are also conflicting results. The aim of this review is to describe the state of the art on the topic under investigation.

Verified
Journal Article
Open access
PDF file
Jessica MaiuoloJessica Maiuolo
Jessica Maiuolo
CCCristina Carresi
Cristina Carresi
Micaela GliozziMicaela Gliozzi
Micaela Gliozzi
RMRocco Mollace
Rocco Mollace
FSFederica Scarano
Federica Scarano
VMVincenzo Mollace
Vincenzo Mollace
The maintenance of the physiological values of blood pressure is closely related to unchangeable factors (genetic predisposition or pathological alterations) but also to modifiable factors (dietary fat and salt, sedentary lifestyle, overweight, inappropriate combinations of drugs, alcohol abuse, smoking and use of psychogenic substances). Hypertension is usually characterized by the presence of a chronic increase in systemic blood pressure above the threshold value and is an important risk factor for cardiovascular disease, including myocardial infarction, stroke, micro- and macro-vascular diseases. Hypertension is closely related to functional changes in the endothelium, such as an altered production of vasoconstrictive and vasodilator substances, which lead to an increase in vascular resistance. These alterations make the endothelial tissue unresponsive to autocrine and paracrine stimuli, initially determining an adaptive response, which over time lead to an increase in risk or disease. The gut microbiota is composed of a highly diverse bacterial population of approximately 1014 bacteria. A balanced intestinal microbiota preserves the digestive and absorbent functions of the intestine, protecting from pathogens and toxic metabolites in the circulation and reducing the onset of various diseases. The gut microbiota has been shown to produce unique metabolites potentially important in the generation of hypertension and endothelial dysfunction. This review highlights the close connection between hypertension, endothelial dysfunction and gut microbiota.